BeOne Medicines (BEIGF) Assets Average (2016 - 2026)

BeOne Medicines (BEIGF) has 11 years of Assets Average data on file, last reported at $8.4 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $8.4 billion, up 42.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 billion (up 42.34% YoY), and the FY2025 annual result was $7.1 billion, up 20.32% from the prior year.
• Assets Average advanced to $8.4 billion in Q1 2026 per BEIGF's latest filing, from $7.9 billion in the prior quarter.
• Over five years, Assets Average peaked at $8.4 billion in Q1 2026 and troughed at $5.6 billion in Q3 2023.
• A 5-year average of $6.5 billion and a median of $5.9 billion in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average soared 44.96% in 2022, then slumped 30.92% in 2023.
• A 5-year view of Assets Average shows it stood at $6.1 billion in 2022, then declined by 7.18% to $5.7 billion in 2023, then rose by 3.72% to $5.9 billion in 2024, then soared by 34.63% to $7.9 billion in 2025, then rose by 5.82% to $8.4 billion in 2026.
• Business Quant data shows BEIGF's Assets Average at $8.4 billion in Q1 2026, $7.9 billion in Q4 2025, and $7.0 billion in Q3 2025.